Ignite Creation Date:
2024-05-06 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 12:55 PM
Study NCT ID:
NCT03691376
Status:
TERMINATED
Last Update Posted:
2024-03-12
First Post:
2018-09-27
Brief Title:
Genetically Engineered Cells NY-ESO-1 TCR Engineered T Cells and HSCs After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Platinum-Resistant Fallopian Tube Carcinoma |
| Platinum-Resistant Ovarian Carcinoma |
| Platinum-Resistant Primary Peritoneal Carcinoma |
| Platinum-Sensitive Fallopian Tube Carcinoma |
| Platinum-Sensitive Ovarian Carcinoma |
| Platinum-Sensitive Primary Peritoneal Carcinoma |
| Recurrent Fallopian Tube Carcinoma |
| Recurrent Ovarian Carcinoma |
| Recurrent Primary Peritoneal Carcinoma |
| Refractory Fallopian Tube Carcinoma |
| Refractory Ovarian Carcinoma |
| Refractory Primary Peritoneal Carcinoma |
Keywords: